QS Investors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

QS Investors’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-5	Closed	-$1K	–	2076
2015 Q4	$1K	Buy	+5	New	+$252	﹤0.01%	1880

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

QS Investors's ITCI Position: Q1 2016 in Review

QS Investors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2016, closing a stake of 5 shares — an estimated $1K sold.

QS Investors first reported a position in ITCI in Q4 2015 and held it in 1 quarter. The position peaked at $1K in Q4 2015. 127 funds tracked by Wall St. Rank hold ITCI as of Q1 2016.

QS Investors reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2016 after selling out during the quarter.
QS Investors sold 5 Intra-Cellular Therapies Inc. shares in Q1 2016, an estimated $1K.
QS Investors first reported a position in Intra-Cellular Therapies Inc. in Q4 2015 and held it in 1 quarter.
QS Investors's Intra-Cellular Therapies Inc. position peaked at $1K in Q4 2015.
127 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2016.

Based on QS Investors's 13F filing for Q1 2016, filed 16 May 2016.